Clinical Trials
12 trialsNCT05325866 2026-02-04
FORTITUDE-301
Amgen
Phase 1/2 Completed
NCT01737502 2025-09-05
Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer
Mayo Clinic
Phase 1/2 Completed
NCT04770688 2024-08-15
AUTOMAN
Shanghai Chest Hospital
Phase 1/2 Completed
NCT03076164 2024-04-02
A Phase 1/2 Trial of Trametinib and Erlotinib in Patients With EGFR-Mutant Lung Adenocarcinomas and Acquired Resistance to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT04046614 2024-02-06
NintNivo
AIO-Studien-gGmbH
Phase 1/2 Completed
NCT00073398 2020-05-28
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Lumos Pharma
Phase 1/2 Completed
NCT01259089 2019-09-11
Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer
Northwestern University
Phase 1/2 Completed
NCT01362790 2019-06-06
SS1P and Pentostatin Plus Cyclophosphamide for Mesothelioma
National Institutes of Health Clinical Center (CC)
Phase 1/2 Completed
NCT00003202 2018-08-10
Gemcitabine Plus Radiation Therapy or Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Wake Forest University Health Sciences
Phase 1/2 Completed
NCT00023673 2017-12-22
Radiation Therapy Combined With Paclitaxel and Carboplatin in Treating Patients With Stage III Non-Small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed
NCT00716456 2015-04-30
Cetuximab in Patients With Lung Adenocarcinoma Receiving Erlotinib That Have Developed "Acquired Resistance" to Erlotinib
Memorial Sloan Kettering Cancer Center
Phase 1/2 Completed
NCT00002577 2013-11-19
Radiation Therapy in Treating Patients With Non-small Cell Lung Cancer
Radiation Therapy Oncology Group
Phase 1/2 Completed